The case for & against
Bull & Bear analysis
HCA Healthcare, Inc. (NYSE: HCA) is a leading provider of healthcare services in the United States, operating a widespread network of hospitals, outpatient facilities, and surgery centers. Positioned within the rapidly evolving healthcare sector, HCA serves a diverse patient base; however, it faces significant challenges due to recent shifts in healthcare policies and coverage dynamics. The company's strategic focus on enhancing operational efficiency, investing in technology, and expanding its service capacities underscores its commitment to quality care while navigating complex regulatory environments.
Bull says
- ↑Q2 2026 revenue of $20.23B (+8.7% YoY) with diluted EPS of $7.62
- ↑19th consecutive quarter of volume growth supports demand resilience
- ↑Over $7B planned capex to add ~1,200 inpatient beds and 250–300 outpatient sites
- ↑Royal London increased stake by 4.7%; analysts rate moderate buy at $462.64 target
- ↑Investments in tech and outpatient services to boost efficiency and margins
- ↑Strong profitability and high earnings yield, plus positive momentum and low volatility
Bear says
- ↓Insured-patient mix down 15%, reducing adjusted EBITDA by ~$400M
- ↓2026 guidance lowered to $77–79.5B revenue and EPS $28.70–30.50
- ↓High leverage risk amid rising interest rates may strain flexibility
- ↓Negative growth and revision signals and high short interest reflect skepticism
- ↓Rising labor and supply costs intensify margin pressures
- ↓Shift to uninsured coverage and policy changes threaten revenue
Investment themes with HCA
Companies repurchasing their own shares
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- We had revenue growth of 6.4%, slightly above the top end of our long-term 4-6% guidance.
- Adjusted EBITDA margin improved 30 basis points compared to the prior year quarter. Salary and benefits, along with other operating expenses, both improved as a percentage of revenue when compared to the prior year.
- We saw an approximate $100 million increase in net benefit in the second quarter of 2025 compared to the prior year quarter due to prior period reconciliation payments and programs accrual time.
Bear points
- Medicare grew 3%, which is slightly below our expectations. Medicaid was down slightly, and self-pay was up slightly. Both were below our expectations and represent our lowest reimbursing payers.
- We now anticipate our supplemental payments full year net benefit to be between flat and $100 million favorable year over year.
- You know, if I think about the other half of our guidance increase, it really relates to our portfolio.